Similar articles

• The clinical rationale for immediate androgen deprivation without estrogen deprivation.

  Pitts WR Jr. Pitts WR Jr. Clin Prostate Cancer. 2003 Sep;2(2):127-8. doi: 10.3816/cgc.2003.n.021. Clin Prostate Cancer. 2003. PMID: 15040875 No abstract available.
• [Reevaluation of MAB therapy and progress of endocrine therapy].

  Klotz L, Payne H, Gillatt D, Keane T, Morris C, Akaza H, Hirao, Akakura K, Fukagai T. Klotz L, et al. Gan To Kagaku Ryoho. 2005 May;32(5):705-28. Gan To Kagaku Ryoho. 2005. PMID: 15934164 Review. Japanese. No abstract available.
• Bicalutamide versus flutamide in combination therapy.

  Labrie F, Candas B. Labrie F, et al. Urology. 1999 Mar;53(3):662-3. doi: 10.1016/s0090-4295(98)00345-8. Urology. 1999. PMID: 10096411 No abstract available.
• Newer approaches to androgen deprivation therapy in prostate cancer.

  Pitts WR Jr. Pitts WR Jr. Urology. 2003 Apr;61(4):882. doi: 10.1016/s0090-4295(02)02547-5. Urology. 2003. PMID: 12670593 No abstract available.
• [Hormonal treatment of cancer of the prostate: review and present status].

  Ganzer R, Wieland WF, Bach T, Rössler W, Blana A. Ganzer R, et al. Dtsch Med Wochenschr. 2007 Jan 26;132(4):161-6. doi: 10.1055/s-2007-959305. Dtsch Med Wochenschr. 2007. PMID: 17230333 Review. German. No abstract available.